Journal article

Plasma Amyloid-beta Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease

Yen Ying Lim, Paul Maruff, Naoki Kaneko, James Doecke, Christopher Fowler, Victor L Villemagne, Takashi Kato, Christopher C Rowe, Yutaka Arahata, Shinichi Iwamoto, Kengo Ito, Koichi Tanaka, Katsuhiko Yanagisawa, Colin L Masters, Akinori Nakamura

Journal of Alzheimer's Disease | IOS PRESS | Published : 2020

Abstract

BACKGROUND: Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear. OBJECTIVE: We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts. METHODS: Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood sampl..

View full abstract

Grants

Awarded by National Center for Geriatrics and Gerontology


Awarded by National Health and Medical Research Council (NHMRC)


Funding Acknowledgements

The AIBL study would like to thank all participants of the study and the clinicians who referred participants. The AIBL study (https://aibl.csiro.au/) is a consortium between Austin Health, CSIRO, Edith Cowan University and the Florey Institute, The University of Melbourne. Partial financial support was provided by the Alzheimer's Association (US), the Alzheimer's Drug Discovery Foundation, an anonymous foundation, the Cooperative Research Centre for Mental Health, CSIRO Science and Industry Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government Operational Infrastructure Support program, the McCusker Alzheimer's Research Foundation, the National Health and Medical Research Council, and the Yulgilbar Foundation. Funding sources had no role in study design, data collection, data analyses or data interpretation. The NCGG study group thank all participants of the study, clinicians who referred patients, all the staff who supported the MULNIAD project, and the NCGG Biobank members for the management of plasma samples. The NCGG study was supported by The Research Funding for Longevity Sciences (25-24 and 26-30) from the National Center for Geriatrics and Gerontology, and partially supported by Research and Development Grants for Dementia from the Japan Agency for Medical Research and Development, AMED. This study is registered under UMIN ID: 000016144.YY Lim is supported by a Career Development Fellowship from the National Health and Medical Research Council (NHMRC) (GNT1162645).